���ϲ�����

Corticosteroids retained 41.92% share of the nasal polyps treatment market in 2025 on the back of favorable pricing and wide prescriber familiarity. Yet biologic therapies within the “Other Drug Class” bracket are expanding at an 8.22% CAGR, propelled by robust real-world effectiveness and multi-cohort label extensions. Antibiotic usage is falling as mechanistic focus shifts from infectious to type 2 inflammatory drivers. Leukotriene modifiers remain niche, serving patients with comorbid asthma yet limited standalone benefit in polyp regression.

The competitive tide is evident in hospital formularies, where biologic utilization in high-surgery-risk cohorts is rising quarter-on-quarter. Dupilumab’s adolescent indication, tezepelumab’s near-approval status, and China’s stapokibart launch intensify attention on disease-modifying results that reduce revision surgeries and cumulative systemic steroid exposure. Payer scrutiny is tightening but long-term cost offsets from fewer operating-room episodes and productivity gains strengthen the biologic value narrative. Post-2028 biosimilar waves should gradually unlock fuller access while sustaining innovation incentives for next-generation cytokine targets.

Nasal sprays delivered 48.01% revenue share in 2025, benefiting from patient-friendly formats and over-the-counter steroid options that manage mild-to-moderate symptoms. Exhalation delivery systems, led by XHANCE’s closed-palate mechanism, are on track for an 8.35% CAGR by 2031 as studies confirm deeper sinus penetration and better polyp shrinkage scores. Oral and injectable routes remain relevant for systemic treatments, especially during acute exacerbations or for biologic dosing every 2–8 weeks. Implantable devices, exemplified by SINUVA and LATERA, occupy an early-adopter niche awaiting further long-term safety data.

Emerging solutions combine handheld battery-assisted atomizers with sensors that log dosing compliance to cloud portals, supporting remote physician oversight. Stryker’s LATERA absorbable implant reportedly saves USD 2,200 per patient compared with functional endoscopic sinus surgery in suitable lateral wall collapse cases. Uptake of such implants remains country-specific, hinging on specialist skill sets and reimbursement scheduling. As device makers refine ergonomics and integrate digital guidance, payers may favor these technologies for their potential to lower intensive surgical episodes.

Hospital pharmacies represented 46.10% of the nasal polyps treatment market size in 2025, reflecting centralized biologic inventories, cold-chain controls, and immediate post-infusion monitoring services. Online pharmacies are growing at a 9.08% CAGR, underpinned by e-prescription laws and patient expectations for doorstep specialty medication delivery with adherence apps. Retail chains hold steady volumes via intranasal sprays, while specialty clinics increasingly manage biologic dispensing under coordinated care agreements.

Health systems integrate tele-ENT consultation portals, enabling remote diagnosis, e-consult coding, and synchronized pharmacy shipments, especially across rural catchments in Asia-Pacific. National regulators now allow electronic prior authorizations and temperature-controlled courier models, sustaining biological integrity to the patient’s refrigerator. Pharmacy benefit managers expand nurse-navigator programs for biologic titration, supporting home-administration paradigms that lower infusion-center overheads and broaden regional reach.

Hospitals accounted for 50.74% revenue share in 2025, backed by superior imaging suites, integrated surgical theaters, and multidisciplinary allergy-pulmonology collaboration. ENT clinics are the fastest, at a 9.21% CAGR, as high-definition endoscopes, cone-beam CT scanners, and biologic inventory financing give single-specialty centers comparable capabilities at lower fixed-cost bases. Ambulatory surgery centers add volume for less complex procedures, such as polypectomy with balloon sinuplasty, while home care garners interest for biologic maintenance in stable patients.

The Global Otolaryngology-Head and Neck Surgery Initiative’s equipment minimums empower emerging-market clinics to perform reliable diagnostics, thereby capturing patient loyalty. AI-driven decision-support platforms filter endoscopic images to grade polyp severity and recommend evidence-based treatment plans, raising clinic throughput. Pay-for-performance models tie reimbursement to patient-reported outcomes, rewarding centers that minimize repeat surgeries and systemic steroid bursts, thus favoring specialized ENT environments.

North America led the nasal polyps treatment market in 2025 with 42.02% share, underpinned by strong prescribing of FDA-cleared biologics, widespread insurance coverage for specialty drugs, and active patient advocacy groups that facilitate early diagnosis. The United States accounts for the bulk of regional revenue, leveraging real-time benefits checks and manufacturer copay programs that offset high list prices. Canada’s provincial drug plans steadily add biologics to formularies following health-technology assessments, while Mexico’s growing private insurance pool is accelerating corticosteroid spray and balloon sinuplasty uptake. Ongoing payer negotiations create heterogeneous access, yet steady commercial uptake has cemented the region’s leadership.

Europe shows balanced growth, supported by centralized EMA reviews that streamline multinational launches. Germany and the United Kingdom anchor clinical research networks and employ stringent cost-effectiveness thresholds, accelerating tender competition and risk-sharing contracts for biologic reimbursement. France and Italy benefit from specialist training programs and universal coverage, keeping surgery queues short and biologic adoption steady. Spain, with upgraded tertiary ENT hubs and improving macroeconomics, is emerging as a significant volume contributor. EU aging demographics and stringent workplace wellness mandates sustain long-term demand.

Asia-Pacific is projected to achieve the fastest 7.18% CAGR through 2031 as healthcare spending expands, infrastructure modernizes, and patient awareness rises. China’s stapokibart approval marked a milestone in domestic innovation and opened the door for locally produced monoclonals at regionally competitive price points. Japan’s robust innovation funding and single-payer insurance framework support high biologic penetration, while Australia and South Korea mirror Western adoption curves. India’s ENT workforce shortfall remains a constraint, though tele-medicine and policy emphasis on noncommunicable diseases could unlock latent demand later this decade. Urban–rural disparities will persist, but incremental expansion of public hospital capacity and private insurance penetration is set to widen treatment access.